Evaxion Retains Global Rights to Gonorrhea Vaccine EVX-B2 After MSD Declines Option

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialEvaxion Biotech ( (EVAX) ) has provided an announcement. On December 19, 2025, Evaxion A/S reported that its collaboration partner MSD chose not to exercise an option to develop Evaxion’s gonorrhea vaccine candidate EVX-B2, leaving Evaxion with global rights and the ability to seek a new licensing partner for the asset. The company emphasized that preclinical data show EVX-B2 protects against gonorrhea, a disease affecting more than 80 million people annually with no approved vaccine, and noted that MSD’s decision does not affect Evaxion’s cash runway, which it says still extends into the second half of 2027; Evaxion also continues its separate mRNA-based EVX-B2 program with Afrigen Biologics and retains potential milestone and royalty upside from MSD’s earlier exercise of an option on a different vaccine candidate, EVX-B3. The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page. Spark’s Take on EVAX Stock According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral. Evaxion Biotech’s overall score is driven by strong technical indicators and positive earnings call highlights, including a significant deal with MSD and promising clinical data. However, financial challenges such as persistent net losses and reliance on debt weigh down the score. The valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. To see Spark’s full report on EVAX stock, click here. More about Evaxion Biotech Evaxion A/S is a Copenhagen-based, clinical-stage TechBio company that uses its proprietary AI-Immunology platform to develop AI-powered vaccines and immunotherapies targeting cancer, bacterial diseases and viral infections. The company has a clinical-stage personalized oncology vaccine pipeline and a preclinical infectious disease pipeline aimed at high unmet medical needs, including candidates such as the gonorrhea vaccine EVX-B2 and other bacterial and viral vaccine projects. Average Trading Volume: 1,632,005 Technical Sentiment Signal: Sell Current Market Cap: $37.02M Find detailed analytics on EVAX stock on TipRanks’ Stock Analysis page.